vs
Side-by-side financial comparison of ECB Bancorp, Inc. (ECBK) and EyePoint, Inc. (EYPT). Click either name above to swap in a different company.
ECB Bancorp, Inc. is the larger business by last-quarter revenue ($9.5M vs $5.3M, roughly 1.8× EyePoint, Inc.). ECB Bancorp, Inc. runs the higher net margin — 27.3% vs -1114.3%, a 1141.6% gap on every dollar of revenue. On growth, ECB Bancorp, Inc. posted the faster year-over-year revenue change (33.8% vs -43.7%). ECB Bancorp, Inc. produced more free cash flow last quarter ($9.0M vs $-63.8M). Over the past eight quarters, ECB Bancorp, Inc.'s revenue compounded faster (23.8% CAGR vs -40.8%).
ECB Bancorp, Inc. (MD) is a US-based bank holding company. It offers a full suite of retail and commercial banking products including deposit accounts, consumer loans, commercial financing and wealth management solutions, primarily serving individuals and small-to-mid enterprises across local markets in Maryland.
EyePoint Pharmaceuticals Inc. is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.
ECBK vs EYPT — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.5M | $5.3M |
| Net Profit | $2.6M | $-59.4M |
| Gross Margin | — | — |
| Operating Margin | 36.7% | -1166.8% |
| Net Margin | 27.3% | -1114.3% |
| Revenue YoY | 33.8% | -43.7% |
| Net Profit YoY | 79.5% | -92.8% |
| EPS (diluted) | $0.32 | $-0.85 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.5M | — | ||
| Q3 25 | $8.8M | — | ||
| Q2 25 | $8.0M | $5.3M | ||
| Q1 25 | $6.9M | $24.5M | ||
| Q4 24 | $7.1M | $11.6M | ||
| Q3 24 | $6.6M | $10.5M | ||
| Q2 24 | $6.3M | $9.5M | ||
| Q1 24 | $6.2M | $11.7M |
| Q4 25 | $2.6M | — | ||
| Q3 25 | $2.4M | — | ||
| Q2 25 | $1.4M | $-59.4M | ||
| Q1 25 | $1.3M | $-45.2M | ||
| Q4 24 | $1.4M | $-41.4M | ||
| Q3 24 | $1.1M | $-29.4M | ||
| Q2 24 | $791.0K | $-30.8M | ||
| Q1 24 | $621.0K | $-29.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 93.0% | ||
| Q2 24 | — | 85.2% | ||
| Q1 24 | — | 93.5% |
| Q4 25 | 36.7% | — | ||
| Q3 25 | 37.0% | — | ||
| Q2 25 | 23.9% | -1166.8% | ||
| Q1 25 | 24.9% | -199.7% | ||
| Q4 24 | 27.3% | -390.4% | ||
| Q3 24 | 23.3% | -311.2% | ||
| Q2 24 | 16.9% | -364.5% | ||
| Q1 24 | 13.4% | -285.2% |
| Q4 25 | 27.3% | — | ||
| Q3 25 | 27.7% | — | ||
| Q2 25 | 18.0% | -1114.3% | ||
| Q1 25 | 18.7% | -184.8% | ||
| Q4 24 | 20.3% | -357.3% | ||
| Q3 24 | 17.2% | -279.0% | ||
| Q2 24 | 12.6% | -325.3% | ||
| Q1 24 | 10.0% | -250.6% |
| Q4 25 | $0.32 | — | ||
| Q3 25 | $0.29 | — | ||
| Q2 25 | $0.17 | $-0.85 | ||
| Q1 25 | $0.16 | $-0.65 | ||
| Q4 24 | $0.18 | $-0.65 | ||
| Q3 24 | $0.14 | $-0.54 | ||
| Q2 24 | $0.09 | $-0.58 | ||
| Q1 24 | $0.07 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $82.8M | $255.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $171.9M | $246.0M |
| Total Assets | $1.6B | $301.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $82.8M | — | ||
| Q3 25 | $201.9M | — | ||
| Q2 25 | $191.0M | $255.7M | ||
| Q1 25 | $143.7M | $318.2M | ||
| Q4 24 | $309.4M | $370.9M | ||
| Q3 24 | $114.8M | $253.8M | ||
| Q2 24 | $108.7M | $280.2M | ||
| Q1 24 | $109.8M | $299.3M |
| Q4 25 | $171.9M | — | ||
| Q3 25 | $169.3M | — | ||
| Q2 25 | $168.3M | $246.0M | ||
| Q1 25 | $168.6M | $298.4M | ||
| Q4 24 | $168.3M | $336.5M | ||
| Q3 24 | $166.0M | $218.7M | ||
| Q2 24 | $166.5M | $228.3M | ||
| Q1 24 | $165.8M | $249.9M |
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.5B | $301.1M | ||
| Q1 25 | $1.5B | $362.6M | ||
| Q4 24 | $1.4B | $418.5M | ||
| Q3 24 | $1.4B | $300.9M | ||
| Q2 24 | $1.3B | $324.2M | ||
| Q1 24 | $1.3B | $329.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.2M | $-62.6M |
| Free Cash FlowOCF − Capex | $9.0M | $-63.8M |
| FCF MarginFCF / Revenue | 94.7% | -1196.5% |
| Capex IntensityCapex / Revenue | 2.2% | 22.9% |
| Cash ConversionOCF / Net Profit | 3.55× | — |
| TTM Free Cash FlowTrailing 4 quarters | $14.2M | $-194.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.2M | — | ||
| Q3 25 | $4.0M | — | ||
| Q2 25 | $1.9M | $-62.6M | ||
| Q1 25 | $-631.0K | $-53.1M | ||
| Q4 24 | $6.2M | $-35.8M | ||
| Q3 24 | $861.0K | $-39.0M | ||
| Q2 24 | $1.4M | $-20.2M | ||
| Q1 24 | $-429.0K | $-31.2M |
| Q4 25 | $9.0M | — | ||
| Q3 25 | $4.0M | — | ||
| Q2 25 | $1.8M | $-63.8M | ||
| Q1 25 | $-649.0K | $-53.4M | ||
| Q4 24 | $6.2M | $-36.2M | ||
| Q3 24 | — | $-40.6M | ||
| Q2 24 | $1.3M | $-21.1M | ||
| Q1 24 | $-449.0K | $-32.4M |
| Q4 25 | 94.7% | — | ||
| Q3 25 | 44.9% | — | ||
| Q2 25 | 23.0% | -1196.5% | ||
| Q1 25 | -9.4% | -218.4% | ||
| Q4 24 | 86.8% | -312.7% | ||
| Q3 24 | — | -385.8% | ||
| Q2 24 | 21.4% | -222.4% | ||
| Q1 24 | -7.2% | -277.0% |
| Q4 25 | 2.2% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 0.6% | 22.9% | ||
| Q1 25 | 0.3% | 1.1% | ||
| Q4 24 | 0.8% | 3.3% | ||
| Q3 24 | 0.0% | 15.0% | ||
| Q2 24 | 0.6% | 9.5% | ||
| Q1 24 | 0.3% | 10.2% |
| Q4 25 | 3.55× | — | ||
| Q3 25 | 1.65× | — | ||
| Q2 25 | 1.32× | — | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | 4.31× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | -0.69× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
